TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05000619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach mailer
Description: Postcard or letter

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach mailer
Description: Postcard or letter

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach mailer
Description: Postcard or letter

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Humor/Salience
Description: Funny cartoon

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doctor's authority
Description: Letter from a doctor

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information about benefits of the appointment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information about benefits of the appointment
Study: NCT05574257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is injected at 25-100ug/kg/min (immediately after spinal anesthesia to the end of surgery) to maintain the BIS at 70-80.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam is injected at 1-20ug/kg/min (immediately after spinal anesthesia to the end of surgery) to maintain the BIS at 70-80.
Study: NCT06140979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playing the game
Description: The intervention is based on a parkour game in which the player runs forward as a cartoon character, avoiding obstacles in front of him/her while collecting gold coins and various props. In this process, players need to stay focused and operate in time to avoid obstacles or collect rewards, and as time goes on, the difficulty of the game increases until eventually they cannot avoid obstacles. As time goes on, the difficulty of the game will increase until the end of the game when you can't avoid the obstacles.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Watching the gameplay video
Description: The intervention consists of a 30-minute non-therapeutic video of a parkour game, which is paused every 10 minutes and requires the patient to click continue until the end of the video. No other action is required.
Study: NCT05812677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
Description: R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Study: NCT05848934

Intervention type: DEVICE
Intervention: magnetic resonance image
Description: Imaging data were collected in a strong magnetic field

Intervention type: DEVICE
Intervention: magnetic resonance image
Description: Imaging data were collected in a strong magnetic field

Intervention type: DEVICE
Intervention: magnetic resonance image
Description: Imaging data were collected in a strong magnetic field

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological scale
Description: Multi dimensional neuropsychological test

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological scale
Description: Multi dimensional neuropsychological test

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological scale
Description: Multi dimensional neuropsychological test
Study: NCT05357131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis without VR (HYP)
Description: HYP will last for 15 minutes including an induction phase of 5 minutes. The hypnotic audio script Heaven of Peace developped/recorded by Pr. M-E. Faymonville will be used.
Study: NCT06076291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG1827
Description: PhaseⅠa will use an accelerated titration and Bayesian optimal interval (AT-BOIN) design with 7 dose cohorts: 0.02mg/kg, 0.2mg/kg, 1mg/kg, 3mg/kg, 6mg/kg, 10mg/kg, and 15mg/kg by IV infusion. Accelerated titration (1 patient) will be only applied to the first cohort.
Study: NCT05687864

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysaccharide superparamagnetic ferric oxide injection
Description: The polysaccharide superparamagnetic ferric oxide injection is a clinical diagnostic reagent
Study: NCT05991544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training and Follow-up According to the Neuman Systems Model
Description: Neuman Systems Model (NSM) it presents a holistic approach to patients by including physiological, spiritual, sociocultural and five major developmental variables
Study: NCT05573269

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FOPE (fish oil + pine extract)
Description: During the experiment period the participants will receive a capsule of pine bark extract (Oligopin® 100mg) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FO (fish oil +placebo)
Description: During the experiment period the participants will receive a capsule of placebo (maltodextrin + magnesium stearate) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.
Study: NCT06248047

Intervention type: PROCEDURE
Intervention: uretheroplasty
Description: 4. When the bulb and bulbar urethra are exposed and before further dissection, the bulbar arteries are located using a directional doppler ultrasound stethoscope and a decision is made to sacrifice the artery with the lowest doppler signal to preserve the contralateral best artery. The bulbar urethra is then mobilized, circumferentially dissected and separated distally from the corpus cavernosum up to the penoscrotal angle to gain sufficient length for a tension-free end-to-end anastomosis without detachment of the bulb from the perineal body. If the dissection is not sufficient to bridge the gap,inter-corporal septal separation or even an inferior pubectomy are performed. The scarred tissue is removed completely, the proximal urethral segment is exposed as usual with spatulation of the healthy urethral ends and end-to-end anastomosis of the urethra over a silicon catheter is performed. No dissection is performed contralaterally at the bulb to preserve the artery of that side.

Intervention type: PROCEDURE
Intervention: uretheroplasty
Description: 4. When the bulb and bulbar urethra are exposed and before further dissection, the bulbar arteries are located using a directional doppler ultrasound stethoscope and a decision is made to sacrifice the artery with the lowest doppler signal to preserve the contralateral best artery. The bulbar urethra is then mobilized, circumferentially dissected and separated distally from the corpus cavernosum up to the penoscrotal angle to gain sufficient length for a tension-free end-to-end anastomosis without detachment of the bulb from the perineal body. If the dissection is not sufficient to bridge the gap,inter-corporal septal separation or even an inferior pubectomy are performed. The scarred tissue is removed completely, the proximal urethral segment is exposed as usual with spatulation of the healthy urethral ends and end-to-end anastomosis of the urethra over a silicon catheter is performed. No dissection is performed contralaterally at the bulb to preserve the artery of that side.
Study: NCT05907941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ciNPT
Description: Following closure of the abdominal donor site, the closed incision will be dressed with the ciNPT system \[V.A.C.ULTA™ Negative Pressure Wound Therapy System (KCI, USA)\] applied by the operating surgeon in a sterile fashion (Figure 2). The ciNPT device will be set at -125mmHg of continuous negative pressure for a period of 7 days or until patient discharge from hospital. Removal of the ciNPT dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied to the abdominal incision unless clinically indicated secondary to dehiscence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Tape Dressings
Description: Following closure of the abdominal donor site, the closed abdominal incision will be dressed with 1-inch Micropore™ Surgical Tape (3M, USA) with an alcohol swab applied to the tape for additional adhesion, by the operating surgeon in a sterile fashion. This dressing will remain in-situ for up to 7 days or until patient discharge from hospital. Removal of the traditional tape dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied unless clinically indicated secondary to dehiscence.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DIEP Breast Reconstruction
Description: All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice. At the Hamilton sites, we will use 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure. At the London sites, we will use 2-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 3-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 4-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DIEP Breast Reconstruction
Description: All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice. At the Hamilton sites, we will use 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure. At the London sites, we will use 2-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 3-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 4-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.
Study: NCT04763681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple HOPES Guided, Internet-Delivered, Self-Help Intervention
Description: Couple HOPES is a guided self-help intervention for individuals with PTSD and their partners based on Cognitive-Behavioral Conjoint Therapy for PTSD (Monson \& Fredman, 2012). This intervention consists of text and video-based content across seven intervention modules and phone and online-based coaching sessions with a paraprofessional. Participants are able to complete these modules in their own home or private location of their choosing. The primary outcomes are PTSD symptoms, relationship satisfaction, and the mental health and wellbeing of partners of those with PTSD.
Study: NCT05732402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: povetacicept
Description: Administered by subcutaneous injection every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: povetacicept
Description: Administered by subcutaneous injection every 4 weeks
Study: NCT06626919

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anito-cel
Description: Anitocabtagene autoleucel BCMA directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-Domain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Lymphodepletion regimen
Description: Standard lymphodepletion regimen subject receive 5 days prior to CAR T infusion
Study: NCT05086211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proprioceptive neuromuscular facilitation
Description: Each session including three proprioceptive neuromuscular facilitation techniques:~Balance training exercises,participants will be treated for 20 minutes with PNF techniques that included;Rhythmic initiation, slow reversal techniques practiced with D1 and D2 pattern in lower limb,repeated contraction and Resisted PNF.The Technique will be performed for 3 days per week in same order on all subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pertubation based balance training
Description: Each session will include a 5-10min warm-up,voluntary tasks intended to induce internal perturbations,voluntary tasks combined with external perturbations and a 5-10mins cool down.The technique will be performed for 2 sets of 10 repetitions on all subjects
Study: NCT05307198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Drug: Oxaliplatin Oxaliplatin 130mg/m2 for inducing chemotherapy in Day 1 every 3 weeks and repeat for two cycles.~The dose of oxaliplatin used for rectal artery infusion was uncertain because there were no previous study. We design this study with Oxaliplatin 85mg/㎡for rectal artery infusion chemotherapy in Day 1 every 3 weeks and repeat for 2 cycles, based on intravenous chemotherapy regimens recommended by NCCN（mFolfox6）.If there were severe side effects caused by oxaliplatin observed within first 5 patients, we would decreasing the dose of oxaliplatin depending on the multidisciplinary discussion of researchers.~We acknowledged that our study did not determine the most appropriate dosage of oxaliplatin used for artery infusion, but rather performed a novel therapeutic method for microsatellite stable locally advanced rectal cancer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectectomy
Description: Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy in Day 1 to Day 14 every 3 weeks and repeat for 4 cycles.
Study: NCT06632613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 capsules, low dose
Description: ENN0403 capsules will be orally administered once a day for 5 consecutive days at low dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
Study: NCT05307198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Anti-PD1 antibody 200mg/m2 in Day 2 after Rectal Artery Infusion Chemotherapy. Repeat every 3 weeks for 2 cycles.
Study: NCT06491901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PS was given according to lung ultrasound score
Description: If the lung ultrasound confirms RDS and LUS is more than 8, a full dose of PS will be promptly administered at 200 mg/kg (Poractant Alfa, Curosurf®). If the lung ultrasound does not indicate RDS or if LUS is 8 or less, clinical monitoring will continue. Should the clinical criteria for NRDS be met, a full dose of PS will be administered at 200 mg/kg (Poractant Alfa, Curosurf®). In terms of the administration method, less-invasive surfactant administration (LISA) will be employed for infants in a non-invasive ventilation state, while those in an invasive ventilation state will receive PS via endotracheal tube.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PS was given according to clinical criteria
Description: In cases where clinical diagnosis confirms NRDS, PS will be administered at a dosage of 200 mg/kg (Poractant Alfa, Curosurf®). LISA will be employed for infants in a non-invasive ventilation state, while those in an invasive ventilation state will receive PS via endotracheal tube. If clinical manifestations do not meet the diagnosis of NRDS, PS will not be administered.
Study: NCT06632613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 capsules, high dose
Description: ENN0403 capsules will be orally administered once a day for 5 consecutive days at high dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the placebo capsules will be administrated through a nasogastric tube/oral gastric tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules will be orally administered once a day for 5 consecutive days based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
Study: NCT06711042

Intervention type: DIAGNOSTIC_TEST
Intervention: functional tests and radiographic analysis
Description: In this observational study, no active interventions or treatments will be administered to the participants. Both groups (Control Group and Experimental Group) will undergo clinical evaluations, including functional tests (WOMAC, Harris Hip Score, Oxford Hip Score, SF-12, TUG) and radiographic analysis (angular measurements). The participants' outcomes will be compared based on their implant placement (within or outside the Functional Safe Zone).

Intervention type: DIAGNOSTIC_TEST
Intervention: functional tests and radiographic analysis
Description: In this observational study, no active interventions or treatments will be administered to the participants. Both groups (Control Group and Experimental Group) will undergo clinical evaluations, including functional tests (WOMAC, Harris Hip Score, Oxford Hip Score, SF-12, TUG) and radiographic analysis (angular measurements). The participants' outcomes will be compared based on their implant placement (within or outside the Functional Safe Zone).
Study: NCT06710483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Dental Telehealth (PDT)
Description: The PDT will be a scripted telehealth interview 3-7 days before the scheduled dental visit to review medical and dental history, to evaluate the participants' needs for the dental visit, and to set an agreed goal for the dental visit using shared decision making. The goal wlll be one of the following: Goal 1: exam cleaning only, Goal 2: exam and cleaning, Goal 3: exam, radiographs, and cleaning.
Study: NCT06721559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empower@Home: An online cognitive-behavioral therapy self-care program for geriatric depression
Description: Empower@Home is an online self-help intervention based on cognitive behavioral therapy principles designed to treat depressive symptoms in older adults. The intervention has three components: 9 interactive self-paced online sessions, printed workbook that goes along the online sessions for exercises and homework, and telephone coaching by a trained staff from a social service agency serving older adults. The online sessions contain entertainment elements in the form of a character-driven story of a homebound older adults, video-based psycho-educational content, voice-over instructions, interactive exercises, and weekly home practice assignments.

Intervention type: OTHER
Group type: OTHER
Intervention: Telephone friendly visits
Description: Participants in the waitlist control group will receive attention control through biweekly telephone-friendly visitors. Trained project staff will call participants to provide companionship, emotional support, and a friendly conversation. In addition, the callers will conduct a biweekly assessment of depressive symptoms using the patient health questionnaire (PHQ-9), to mirror the biweekly in-app PHQ-9 assessments with the experimental group.
Study: NCT06550882

Intervention type: DRUG
Intervention: OBIZUR
Description: OBIZUR injection.
Study: NCT06729892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine at low dose
Description: Esketamine at low dose was administered(0.2mg· kg-1, 5 ug· kg-1 continuous infusion) and drug dosage was adjusted(propofol and remifentanil) based on the new BIS baseline ( calculated from the pilot study).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine at low dose
Description: Esketamine at low dose was administered(0.2mg· kg-1, 5 ug· kg-1 continuous infusion) and drug dosage was adjusted(propofol and remifentanil) based on the new BIS baseline ( calculated from the pilot study).
Study: NCT05973721

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: phage
Description: The treatment group was given one phage each time, once a day for two weeks
Study: NCT06729892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new BIS baseline
Description: Close-loop TCI control was under new BIS baseline(calculated from pilot study) in the presence of esketamine at low dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: an equivalent dose of saline
Description: An equivalent dose of saline was given and closed-loop control stared.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: original BIS baseline
Description: Drug dosage was adjused under close-loop control based on original BIS baseline.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: original BIS baseline
Description: Drug dosage was adjused under close-loop control based on original BIS baseline.
Study: NCT06759701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Participants will perform weekly self-injection of tirzepatide as standard of care, following manufacturer instructions
Study: NCT06762288

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Sedation and local anesthesia to the surgical field will be applied as standard procedure and unilateral USG-guided TAP block will be performed to the patients who will undergo TAVİ.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia and sedation
Description: Sedation and local anesthesia to the surgical field will be applied to the patients who will undergo TAVİ.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Local anesthesia and sedation
Description: Sedation and local anesthesia to the surgical field will be applied to the patients who will undergo TAVİ.
Study: NCT06761469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementing active-case finding strategies
Description: Implementation of a multifactorial active-case finding strategy, including: (1) raising awareness among the population about leprosy; (2) theoretical and practical educational training for healthcare workers; (3) georeferencing of historical and existing cases in the municipality (from 2012 to 2023) and of new cases diagnosed throughout the study (dynamic changes); (4) screening tools for signs/symptoms of the disease (application of Leprosy Suspicion Questionnaire); and (5) serological profile (rapid test) of patients with reported signs/symptoms (positive answers Leprosy Suspicion Questionnaire).
Study: NCT06773143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine at low dose
Description: After the induction of general anesthesia, patients in the esketamine group will receive a continuous infusion of esketamine (0.3 mg/kg/h) until the end of the operation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (0.9% NaCl)
Description: After the patient's general anesthesia induction is completed, normal saline will be continuously infused until the end of the operation, and the infusion volume is the same as that of the esketamine group.